La Jolla Pharmaceutical Co (LJPC) Stock Rockets On COVID-19 News

La Jolla Pharmaceutical Company LJPC Stock News

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is making a dramatic run for the top this morning. The stock is trading on gains of more than 25% in the premarket after announcing that it will be sending a treatment to Italy for coronavirus patients. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

LJPC Stock Soars After Saying It Will Send GIAPREZA To Italy

As mentioned above, La Jolla Pharmaceutical Company is flying in the market this morning after saying that it will send GIAPREZA to Italy to treat coronavirus patients. In the release, the company said that the treatment will be used under a compassionate use program in patients with COVID-19 related septic shock.

LJPC said that the treatment is being made available due to the request of multiple doctors. In particular Alberto Zangrillo, M.D., Full Professor of Anesthesia and Intensive Care and Giovanni Landoni, M.D., Associate Professor of Anesthesia and Intensive Care at San Raffaele Hospital in Milan, both requested the compassionate use of the drug.

While the European Commission has approved GIAPREZA, the drug is not yet commercially available. However, under italian law, medicines for life-threatening and rare illnesses can be made available prior to commercial availability under a compassionate use program. That’s exactly what LJPC is doing here.

In a statement, Lakmir Chawla, M.D., the company’s Chief Medical Officer, had the following to offer:

La Jolla is committed to helping patients suffering from life-threatening diseases, and we hope that GIAPREZA will positively impact these patients.

Why This News Is Exciting

First and foremost, any treatment that helps coronavirus patients is exciting news. After all, there have been well over 100,000 cases of the virus with more than 4,000 deaths as it spreads around the world. Viable treatment options will be key to getting this pandemic under control. La Jolla Pharmaceutical Company is providing a key treatment.

Importantly, septic shock is a real danger. In fact, about 14% of patients infected with COVID-19 will require hospitalization. About a third of these patients will become critically ill. At this stage of the virus, we see respiratory failure, septic shock and/or multiple organ failure. Unfortunately, about half of critically ill patients will die of coronavirus.

LJPC has an opportunity to help a large amount of patients in the most critical stage of COVID-19 infection. With an adequate treatment for septic shock associated with the virus, the company may be able to reduce the percentage of deaths that happen in coronavirus cases. Of course, this is an overwhelmingly valuable proposition.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.